Table 1.
Clinical indications of the different immune checkpoint inhibitors
| Immune checkpoint inhibitor | Target | Indications |
|---|---|---|
| Ipilimumab | CTLA-4 |
Colorectal cancer, metastatic (microsatellite instability-high or mismatch repair deficient in combination with nivolumab) Melanoma, unresectable, or metastatic in combination with nivolumab Melanoma, adjuvant treatment Advanced renal cell cancer, in combination with nivolumab |
| Pembrolizumab | PD-1 |
Recurrent or metastatic cervical cancer Advanced or metastatic gastric cancer Head and neck cancer, squamous cell, unresectable/recurrent or metastatic, alone or in combination with chemotherapy Advanced hepatocellular carcinoma Hodgkin lymphoma, classical, relapsed or refractory Melanoma, adjuvant treatment Melanoma, unresectable or metastatic Merkel cell carcinoma, recurrent or metastatic Microsatellite instability-high cancer, unresectable or metastatic NSCLC, stage III or metastatic, single-agent therapy NSCLC, metastatic, non-squamous, combination therapy with chemotherapy Primary mediastinal large B cell lymphoma, relapsed or refractory Advanced renal cell carcinoma Small cell lung cancer, metastatic Urothelial carcinoma, locally advanced or metastatic |
| Nivolumab | PD-1 | Like pembrolizumab |
| Cemiplimab | PD-1 | Cutaneous squamous cell carcinoma, metastatic or locally advanced |
| Atezolizumab | PD-L1 |
Breast cancer (triple-negative), locally advanced or metastatic in combination with nab-paclitaxel NSCLC, metastatic: first line with bevacizumab, paclitaxel, and carboplatin Previously-treated NSCLC: monotherapy Small cell lung cancer, extensive-stage: first-line treatment with carboplatin and etoposide Urothelial carcinoma, locally advanced or metastatic |
| Durvalumab | PD-L1 |
NSCLC (stage III), unresectable, initiated within 6 weeks after chemo-radiotherapy Urothelial carcinoma, locally advanced or metastatic |
| Avelumab | PD-L1 |
Metastatic Merkel cell carcinoma Advanced renal cell carcinoma, in combination with axitinib Urothelial carcinoma, locally advanced or metastatic |
CTLA4 Cytotoxic T-lymphocyte antigen 4, NSCLC Non-small cell lung cancer, PD-1 Programmed cell death protein 1, PD-L1 Programmed cell death protein ligand 1